Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Diseases

Inclusion Criteria:

Histologically confirmed hematological disease, including any of the following:

Chronic lymphocytic leukemia

Absolute lymphocytosis > 5,000/µL
Morphologically mature lymphocytes with < 55% prolymphocytes
Lymphocyte phenotype with expression of CD19 and CD5
Absence of CD23 expression allowed provided disease is morphologically distinguished from mantle cell lymphoma

Prolymphocytic leukemia

Absolute lymphocytosis > 5,000/µL
Morphologically mature lymphocytes with > 55% prolymphocytes

Non-Hodgkin's or Hodgkin's lymphoma

Any WHO classification histologic subtype
Diagnosis by core biopsy allowed provided there is adequate tissue for diagnosis and immunophenotyping
Diagnosis by bone marrow biopsy not acceptable for follicular lymphomas

Multiple myeloma

Has received ≥ 1 prior treatment regimen
Has a partial response or greater by the Blade Criteria
Patients who achieved complete remission are eligible

Acute myeloid leukemia

Documented control (i.e., < 10% bone marrow blasts and no circulating blasts)

Myelodysplastic syndromes

Documented disease as defined by WHO or French-American-British Cooperative group criteria
Chronic myelogenous leukemia
Patients with atypical chronic myelogenous leukemia (i.e., absent Philadelphia chromosome) are eligible

Polycythemia vera

Documented disease as defined by WHO criteria (i.e., A1 + A2, and any other category A, OR A1 + A2, and any 2 category B):

A1: Total red blood cell mass > 25% above mean normal predicted value OR hemoglobin > 18.5 g/dL in males, 16.5 g/dL in females (hematocrit ≥ 60% in males or ≥ 56% in females)
A2: No cause of secondary erythrocytosis (absence of familial erythrocytosis, no elevation of epoetin alfa [EPO] due to hypoxia, high oxygen affinity hemoglobin, truncated EPO receptor, or inappropriate ectopic EPO production)
A3: Splenomegaly
A4: Clonal genetic abnormality other than the Philadelphia chromosome
A5: Endogenous erythroid colony formation in vitro
B: Platelet count > 400,000/mm³, WBC > 12,000/mm³, bone marrow biopsy with prominent erythroid and megakaryocytic proliferation, and low serum EPO

Chronic idiopathic myelofibrosis

Documented disease as defined by WHO criteria
Must have a HLA-identical donor, a matched unrelated donor, or a HLA 9/10 related donor meeting the following criteria:

HLA-identical sibling (6/6)

Serologic typing for class I (A, B)
Molecular typing for class II (DRB1)

9/10 matched related donor

High-resolution molecular typing at HLA-A, B, C, DRB1, and DQB1
Only a single mismatch at one class I or II allele allowed

10/10 matched unrelated donor

Molecular identity at HLA-A, B, C, DRB1, and DQB1 by high-resolution typing
Syngeneic donors are not eligible
Creatinine clearance ≥ 40 mL/min
Bilirubin ≤ 3 times upper limit of normal (ULN)
AST ≤ 3 times ULN
DLCO ≥ 40% with no symptomatic pulmonary disease
LVEF ≥ 30% by cardiac MRI or echocardiogram with no symptomatic cardiac disease
Fertile patients willing to use effective contraception

Exclusion Criteria:

Uncontrolled diabetes mellitus
Active serious infection
Known hypersensitivity to E. coli-derived products
Known HIV positivity

History of another malignancy*, meeting the following criteria:

Non-skin malignancy or melanoma within the past 5 years
Concomitant malignancy that has not been curatively treated
NOTE: *However, cancer survivors who have undergone potentially curative therapy for a prior malignancy at least 5 years before enrollment and are deemed at low risk of < 30% for recurrence by their treating physicians is considered
Pregnant or nursing